Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -25,47k | 2,43M | Sale to Issuer | 95,59 | 27,77k | -47,84% |
| 2026-05-26 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -2,05k | 199,66k | Verkauf | 97,35 | 5,97k | -25,58% |
| 2026-05-26 | Mr. Jean-Jacques BienaimeIndependent Director | -13,06k | 164,15k | Derivative Exercise and Sale | 84,53 - 97,10 | 20,26k | - |
| 2026-05-26 | Mr. Jean-Jacques BienaimeIndependent Director | 1,94k | 164,07k | Derivative Exercise and Retained Stock | 84,53 | 20,26k | 10,59% |
| 2026-05-19 | Mr. Paul J. ClancyIndependent Director | -15,00k | 156,00k | Derivative Exercise and Sale | 84,53 - 94,93 | 21,22k | - |
| 2026-05-08 | Baker Bros. Advisors LPUnternehmen | 30,00k | 2,54M | Derivative Exercise and Retained Stock | 84,53 | 31,07M | 0,10% |
| 2026-04-17 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 505,32k | Derivative Exercise and Sale | 64,25 - 96,50 | 5,14k | - |
| 2026-03-25 | Mr. Matteo TrottaInsider | -537,00 | 49,53k | Sale to Issuer | 92,23 | 3,72k | -12,61% |
| 2026-03-17 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 581,82k | Derivative Exercise and Sale | 61,18 - 94,24 | 5,14k | - |
| 2026-02-19 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -18,67k | 734,09k | Derivative Exercise and Sale | 61,18 - 100,91 | 5,14k | - |
| 2026-02-02 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -111,00 | 11,40k | Sale to Issuer | 102,67 | - | - |
| 2026-02-02 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -185,00 | 18,99k | Sale to Issuer | 102,67 | 11,51k | -1,58% |
| 2026-01-20 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -429,00 | 44,02k | Sale to Issuer | 102,62 | 9,05k | -4,52% |
| 2026-01-07 | Mr. Mohamed Khairie IssaExec. VP & Head of U.S. Commercial | -10,86k | 1,18M | Verkauf | 109,07 | - | - |
| 2026-01-06 | Mr. Mohamed Khairie IssaExec. VP & Head of U.S. Commercial | -8,26k | 881,44k | Sale to Issuer | 106,66 | - | - |
| 2026-01-05 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -15,63k | 1,59M | Verkauf | 101,70 | 0,00 | -100,00% |
| 2025-12-31 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -13,29k | 1,31M | Sale to Issuer | 98,77 | 15,63k | -45,95% |
| 2025-12-31 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -254,00 | 25,09k | Sale to Issuer | 98,77 | 3,36k | -7,03% |
| 2025-12-19 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -2,77k | 11,76k | Derivative Exercise and Sale | 95,76 - 100,00 | 7,81k | - |
| 2025-12-18 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -600,00 | 58,95k | Verkauf | 98,25 | 7,81k | -7,14% |
| 2025-12-16 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -58,33k | 5,68M | Verkauf | 97,26 - 97,42 | 0,00 | -100,00% |
| 2025-12-10 | Dr. Patrick MayesVP of Biotherapeutic Research | -5,81k | 554,97k | Verkauf | 94,94 - 95,58 | 153,00 | -97,43% |
| 2025-12-08 | Mr. Herve HoppenotInsider | -2,84k | 274,92k | Sale to Issuer | 96,70 | 256,16k | -1,10% |
| 2025-12-01 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -22,66k | 2,32M | Verkauf | 102,51 - 102,96 | 0,00 | -100,00% |
| 2025-12-01 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -17,09k | 1,74M | Sale to Issuer | 102,04 | 0,00 | -100,00% |
| 2025-12-01 | Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations | -326,00 | 33,27k | Sale to Issuer | 102,04 | 58,33k | -0,56% |
| 2025-11-21 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -769,00 | 79,04k | Verkauf | 102,00 - 103,00 | 8,41k | -8,38% |
| 2025-11-17 | Ms. Sheila A. DentonInsider | -278,00 | 11,15k | Derivative Exercise and Sale | 64,25 - 104,36 | 656,00 | - |
| 2025-11-10 | Mr. Herve HoppenotInsider | -187,50k | 19,77M | Verkauf | 105,46 | 256,16k | -42,26% |
| 2025-11-05 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -5,23k | 47,94k | Derivative Exercise and Sale | 83,83 - 102,20 | 2,56k | - |
| 2025-11-04 | Ms. Sheila A. DentonInsider | -598,00 | 25,89k | Derivative Exercise and Sale | 58,06 - 101,36 | 656,00 | - |
| 2025-11-03 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -3,07k | 289,02k | Verkauf | 94,02 | - | - |
| 2025-10-15 | Ms. Sheila A. DentonInsider | -277,00 | 5,78k | Derivative Exercise and Sale | 64,25 - 85,13 | 656,00 | - |
| 2025-10-02 | Ms. Sheila A. DentonInsider | -599,00 | 17,72k | Derivative Exercise and Sale | 58,06 - 87,65 | 656,00 | - |
| 2025-10-03 | Ms. Sheila A. DentonInsider | -3,50k | 299,48k | Verkauf | 85,54 | 656,00 | -84,22% |
| 2025-10-02 | Ms. Sheila A. DentonInsider | -3,13k | 270,06k | Sale to Issuer | 86,28 | 656,00 | -82,67% |
| 2025-10-01 | Dr. Patrick MayesVP of Biotherapeutic Research | -1,57k | 136,03k | Sale to Issuer | 86,70 | 5,96k | -20,84% |
| 2025-10-01 | Mr. Lee J. HeesonExec. VP & Head of Incyte International | -463,00 | 40,14k | Sale to Issuer | 86,70 | - | - |
| 2025-09-16 | Ms. Sheila A. DentonInsider | -278,00 | 5,25k | Derivative Exercise and Sale | 64,25 - 83,15 | 657,00 | - |
| 2025-09-02 | Ms. Sheila A. DentonInsider | -598,00 | 16,09k | Derivative Exercise and Sale | 58,06 - 84,97 | 656,00 | - |
| 2025-08-15 | Ms. Sheila A. DentonInsider | -277,00 | 6,25k | Derivative Exercise and Sale | 64,25 - 86,81 | 657,00 | - |
| 2025-08-04 | Ms. Sheila A. DentonInsider | -598,00 | 10,59k | Derivative Exercise and Sale | 58,06 - 75,77 | 656,00 | - |
| 2025-07-21 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -3,71k | 251,79k | Verkauf | 67,94 | 2,56k | -59,15% |
| 2025-07-16 | Dr. Barry P. FlannellyInsider | -1,34k | 91,60k | Verkauf | 68,36 | 13,00 | -99,04% |
| 2025-07-16 | Dr. Vijay K. IyengarInsider | -983,00 | 67,20k | Verkauf | 68,36 | 2,79k | -26,07% |
| 2025-07-15 | Ms. Sheila A. DentonInsider | -3,33k | 18,68k | Derivative Exercise and Sale | 64,25 - 69,86 | 656,00 | - |
| 2025-07-16 | Ms. Sheila A. DentonInsider | -785,00 | 53,66k | Verkauf | 68,36 | 656,00 | -54,48% |
| 2025-07-15 | Ms. Sheila A. DentonInsider | -703,00 | 47,98k | Sale to Issuer | 68,25 | 656,00 | -51,73% |
| 2025-07-15 | Mr. Matteo TrottaInsider | -182,00 | 12,42k | Sale to Issuer | 68,25 | 1,90k | -8,75% |
| 2025-07-14 | Dr. Pablo J. CagnoniPresident and Global Head of R&D | -3,91k | 268,94k | Sale to Issuer | 68,25 - 69,98 | 5,14k | -43,20% |
| 2025-07-14 | Ms. Paula J. SwainInsider | -1,01k | 69,50k | Sale to Issuer | 68,25 - 69,98 | 69,09k | -1,44% |
| 2025-07-14 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -14,95k | 1,02M | Verkauf | 68,47 | 6,27k | -70,47% |
| 2025-07-14 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -3,15k | 217,75k | Sale to Issuer | 68,25 - 69,98 | 6,27k | -33,46% |
| 2025-07-14 | Ms. Christiana StamoulisInsider | -2,85k | 197,08k | Sale to Issuer | 68,25 - 69,98 | 61,75k | -4,41% |
| 2025-07-15 | Dr. Vijay K. IyengarInsider | -1,18k | 82,23k | Verkauf | 69,86 | 3,77k | -23,79% |
| 2025-07-14 | Dr. Vijay K. IyengarInsider | -1,43k | 98,70k | Sale to Issuer | 68,25 - 69,98 | 3,77k | -27,51% |
| 2025-07-14 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -1,28k | 88,22k | Sale to Issuer | 68,25 - 69,98 | 9,15k | -12,23% |
| 2025-07-15 | Dr. Barry P. FlannellyInsider | -1,19k | 83,27k | Verkauf | 69,86 | 1,35k | -46,84% |
| 2025-07-14 | Dr. Barry P. FlannellyInsider | -2,06k | 142,39k | Sale to Issuer | 68,25 - 69,98 | 1,35k | -60,39% |
| 2025-07-14 | Mr. Herve HoppenotInsider | -9,67k | 668,83k | Sale to Issuer | 68,25 - 69,98 | 443,66k | -2,13% |
| 2025-07-02 | Ms. Paula J. SwainInsider | -6,29k | 428,45k | Sale to Issuer | 68,17 | 66,73k | -8,61% |
| 2025-07-02 | Mr. Thomas TrayPrincipal Financial Officer, VP of Finance & CAO | -897,00 | 61,15k | Sale to Issuer | 68,17 | 7,65k | -10,49% |
| 2025-07-02 | Dr. Steven H. SteinExec. VP, Head of Late-stage Development & Chief Medical Officer | -12,71k | 866,71k | Sale to Issuer | 68,17 | 17,51k | -42,06% |
| 2025-07-02 | Ms. Christiana StamoulisInsider | -11,59k | 790,02k | Sale to Issuer | 68,17 | 58,40k | -16,56% |
| 2025-07-03 | Dr. Barry P. FlannellyInsider | -10,90k | 743,04k | Verkauf | 68,15 | 13,00 | -99,88% |
| 2025-07-02 | Dr. Barry P. FlannellyInsider | -9,06k | 617,28k | Sale to Issuer | 68,17 | 13,00 | -99,86% |
| 2025-07-02 | Ms. Sheila A. DentonInsider | -599,00 | 6,32k | Derivative Exercise and Sale | 58,06 - 68,61 | 656,00 | - |
| 2025-07-03 | Dr. Vijay K. IyengarInsider | -8,62k | 587,28k | Verkauf | 68,15 - 68,16 | 2,79k | -75,55% |
| 2025-07-02 | Dr. Vijay K. IyengarInsider | -6,81k | 464,17k | Sale to Issuer | 68,17 | 2,79k | -70,95% |
| 2025-07-02 | Mr. Herve HoppenotInsider | -42,77k | 2,92M | Sale to Issuer | 68,17 | 432,28k | -9,00% |
| 2025-06-10 | Dr. Susanne SchaffertInsider | -849,00 | 59,49k | Sale to Issuer | 70,07 | 4,87k | -14,84% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
